8-K: Cabaletta Bio's Rese-cel Shows Promise Without Preconditioning

Cabaletta Bio reports positive early clinical and translational data for rese-cel in pemphigus vulgaris patients without preconditioning.

Summary

• Cabaletta Bio presented new clinical and translational data from the RESET-PV trial evaluating rese-cel (resecabtagene autoleucel) in three evaluable pemphigus vulgaris (PV) patients without preconditioning.
• Rese-cel demonstrated similar CAR T cell expansion and contraction kinetics compared to trials with preconditioning.
• All three patients experienced substantial B cell depletion within the first month post-infusion, with two achieving complete peripheral B cell depletion.
• Rapid reduction in autoantibodies to desmoglein was observed in the two patients with complete B cell depletion.
• Meaningful early clinical responses were seen in all three patients, with Pemphigus Disease Area Index (PDAI) activity scores improving from 24 to 10 (Patient 1, 4 mo), 83 to 3 (Patient 2, 3 mo), and 22 to 2 (Patient 3, 1 mo).
• Rese-cel was generally well tolerated, with no immune effector cell-associated neurotoxicity syndrome (ICANS) reported.
• One patient experienced transient fever (grade 1 cytokine release syndrome), and another required a less intense course of steroids for a disease flare.
• All three patients remained off immunomodulators as of the data cut-off (September 11, 2025), and two are off or tapering steroids.
• The company plans to expand patient enrollment in the RESET-PV trial at the current dose and explore incorporating no preconditioning regimens in other RESET clinical trial cohorts.
• Cabaletta Bio anticipates a Biologics License Application (BLA) submission for myositis in 2027, with registrational cohorts expected to initiate in 2025.

Sentiment

Score: 9

Explanation: The filing presents highly positive early clinical and translational data for rese-cel without preconditioning, indicating a significant de-risking of the program and potential for broader market access. The safety profile is favorable, and clinical responses are meaningful. This represents a major step forward for the company's pipeline.

Positives

• Rese-cel achieved similar CAR T cell expansion and contraction kinetics without preconditioning, simplifying the treatment regimen.
• Complete peripheral B cell depletion was observed in two of three patients, leading to rapid reduction in autoantibodies.
• Meaningful early clinical responses were observed in all three patients, with significant PDAI score improvements (e.g., 83 to 3, 22 to 2).
• The therapy was generally well tolerated, with no ICANS reported and only one Grade 1 CRS event.
• All three patients remained off immunomodulators, and two were off or tapering steroids, indicating potential for durable, drug-free responses.
• The ability to administer rese-cel without preconditioning could expand patient access and simplify the treatment process.
• FDA alignment has been achieved for registrational cohorts in the RESET-Myositis trial, with a BLA submission planned for 2027.
• All adult Phase 1/2 cohorts within the myositis, lupus, scleroderma, and myasthenia gravis RESET trials are fully enrolled as of September 30, 2025.

Negatives

• Patient 2 experienced a disease flare requiring steroids in the first two weeks post-infusion, though the course was less intense than prior flares.
• The data presented is from a small cohort of only three evaluable patients, which limits generalizability.
• One patient (PV-1M-1) showed limited impact on autoantibodies despite PDAI improvement, suggesting variability in response mechanisms.

Risks

• Risks related to regulatory filings and potential clearance.
• The risk that signs of biologic activity or persistence may not inform long-term results.
• Cabaletta's ability to demonstrate sufficient evidence of safety, efficacy, and tolerability in its preclinical studies and clinical trials of rese-cel.
• The risk that results observed with similarly-designed constructs employed in academic publications are not indicative of the results we seek to achieve with rese-cel.
• Risks that results from one program may not translate to results for another program.
• Risks that modifications to trial design or approach may not have the intended benefits and that the trial design may need to be further modified.
• Risks related to clinical trial site activation, delays in enrollment generally or enrollment rates that are lower than expected.
• Delays related to assessment of clinical trial results.
• Risks related to unexpected safety or efficacy data observed during clinical studies.
• Risks related to volatile market and economic conditions and public health crises.
• Cabaletta's ability to retain and recognize the intended incentives conferred by Orphan Drug Designation and Fast Track Designation or other designations for its product candidates.
• Risks related to Cabaletta's ability to protect and maintain its intellectual property position.
• Risks related to fostering and maintaining successful relationships with Cabaletta's collaboration and manufacturing partners.
• Uncertainties related to the initiation and conduct of studies and other development requirements for its product candidates.
• The risk that any one or more of Cabaletta's product candidates will not be successfully developed and/or commercialized.
• The risk that the initial or interim results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies.

Future Outlook

Cabaletta Bio plans to expand patient enrollment in the RESET-PV trial at the current dose and potentially evaluate higher doses of rese-cel in PV patients. The company is also pursuing the incorporation of no preconditioning regimens in certain other RESET clinical trial program cohorts. They anticipate communicating updates on their no preconditioning strategy in PV and other autoimmune indications, along with broader clinical updates from ongoing RESET trials, at upcoming medical meetings. A Biologics License Application (BLA) submission for myositis is expected in 2027, with registrational cohorts anticipated to begin enrollment in 2025. FDA alignment on pivotal trial designs for SLE/LN and scleroderma is expected in the second half of 2025, and for myasthenia gravis in the first half of 2026.

Management Comments

• David J. Chang, M.D., Chief Medical Officer, stated that the data provides preliminary evidence that a single infusion of rese-cel without preconditioning can achieve complete B cell depletion and meaningful early clinical responses with a simplified regimen that can expand access to patients who may desire a treatment option without preconditioning.
• Management plans to first expand patient enrollment in the RESET-PV trial at the current dose and potentially evaluate higher doses of rese-cel in PV patients, as warranted.
• Management is pursuing the incorporation of no preconditioning regimens in certain other RESET clinical trial program cohorts.
• Management looks forward to communicating updates on the no preconditioning strategy in PV as well as in other autoimmune indications, along with broader clinical updates from ongoing RESET trials, at upcoming medical meetings.

Industry Context

The successful demonstration of rese-cel's efficacy and safety without preconditioning agents like cyclophosphamide and fludarabine represents a significant advancement in the CAR T cell therapy landscape for autoimmune diseases. Preconditioning regimens are often associated with increased toxicity and complexity, limiting patient access. This simplified approach could broaden the applicability of CAR T therapy, making it more accessible and potentially safer for a wider range of autoimmune patients. This positions Cabaletta Bio favorably against competitors by offering a potentially less burdensome treatment option, aligning with a broader industry trend towards de-risking and simplifying advanced therapies.

Comparison to Industry Standards

• Rese-cel's CAR T cell expansion and contraction kinetics without preconditioning were similar to translational data reported from other RESET trials that utilized preconditioning, suggesting comparable biologic activity with a simplified regimen.
• The observed B cell depletion and BAFF induction in patients without preconditioning were within the range seen in patients dosed with rese-cel plus preconditioning, indicating deep B cell depletion in the tissue comparable to more intensive regimens.
• The safety profile, with no ICANS and a Grade 1 CRS rate similar to that observed in patients receiving preconditioning (1/3 or 33% in non-PC PV trial vs. 11/32 or 34% in PC trials), suggests a favorable safety profile for the simplified regimen.
• The company highlights that rese-cel's binder has similar in vitro and in vivo activity to the academic FMC63 binder used in other autoimmune CAR T studies, and uses the same weight-based dose as in academic studies, providing a relevant context for comparison to existing research.

Stakeholder Impact

• **Shareholders/Investors**: Positive impact due to promising clinical data, potential for expanded market opportunities, and a simplified treatment regimen, which could accelerate development and commercialization.
• **Patients**: Highly positive impact as the simplified regimen (without preconditioning) could offer a less toxic and more accessible treatment option for severe autoimmune diseases, potentially leading to durable, drug-free remission.
• **Employees**: Positive impact from continued progress in clinical development and a clear path towards regulatory submissions, fostering a strong sense of purpose and job security.
• **Regulatory Authorities**: The data supports the potential for innovative, less burdensome CAR T cell therapy regimens, which could influence future regulatory guidelines for autoimmune cell therapies.
• **Healthcare Providers**: The simplified regimen could make CAR T cell therapy more manageable to administer, potentially increasing adoption and reducing logistical complexities.

Next Steps

• Expand patient enrollment in the RESET-PV trial at the current dose.
• Potentially evaluate higher doses of rese-cel in PV patients.
• Incorporate no preconditioning regimens in certain other RESET clinical trial program cohorts.
• Communicate updates on the no preconditioning strategy in PV and other autoimmune indications at upcoming medical meetings.
• Present complete Phase 1/2 RESET-Myositis data and interim RESET-SSc & RESET-SLE data at ACR (Oct 24-29).
• Present initial RESET-MG clinical data at AANEM (Oct 29).
• Anticipate FDA alignment on pivotal trial design for SLE/LN and scleroderma in 2H25.
• Initiate enrollment in myositis registrational cohorts in 2025.
• Anticipate FDA alignment on pivotal trial design for myasthenia gravis (MG) in 1H26.
• Plan for Biologics License Application (BLA) submission in myositis in 2027.

Key Dates

Recommendation

The filing presents compelling early clinical and translational data for rese-cel without preconditioning, a significant de-risking event for Cabaletta Bio's lead program. The ability to achieve similar efficacy and safety with a simplified regimen broadens the potential patient population and accelerates the path to market. This positive development, coupled with clear regulatory alignment for myositis and upcoming data readouts for other indications, positions the company for substantial future growth and warrants a strong buy recommendation for seasoned investors.

Keywords

Cabaletta Bio, rese-cel, CABA-201, CAR T cell therapy, autoimmune disease, pemphigus vulgaris, RESET-PV trial, no preconditioning, B cell depletion, clinical data, ESGCT, biotechnology, immunology, cell therapy